secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phio Pharmaceuticals Corp. (PHIO)
CIK:        0001533040
Form:       8-K
Filed at:   2023-02-22T23:59:59+00:00
Accession:  0001683168-23-001075
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phio Pharmaceuticals appoints Robert Bitterman as President and CEO effective Feb 20, 2023
--------------------------------------------------------------------------------

- Bitterman, previously interim CEO since Sep 2022, appointed permanent President and CEO and remains Chair of the Board.
- Employment agreement provides $440,000 base salary, up to 40% annual bonus, and 11,000 RSUs vesting over 2 years.
- Bitterman has prior CEO experience at Cutanea Life Sciences and Isolagen; Board conducted a search before appointment.
- He will continue as principal executive and financial officer; no family relationships or reportable transactions disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1533040/000168316823001075/0001683168-23-001075-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1533040/000168316823001075/phio_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-23-001075

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer